erythromycin (ilosone) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Erythromycin ethylsuccinate (E.E.S.®, ERY-PED®) is an ester of erythromycin base and succinic acid. It is suitable for oral administration. Erythromycin is a macrolide antibiotic, produced by Saccharopolyspora erythraea (formerly Streptomyces erythraeus). It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin does not affect nucleic acid synthesis.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1910 - $29.0950

Australia

$0.3157
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( erythromycin (ilosone), benzoyl peroxide (clearasil) - other name: aktipak )
|
( sulfisoxazole (gantrisin), erythromycin (ilosone) - other name: eryzole )

Alternative names

3''-o-demethylerythromycin | abomacetin | aknemycin | akne-mycin | aknemycin plus | anamycin | a/t/s | bristamycin | c-solve-2 | davercin | e-base | e.e.s. | e.e.s. 200 | e.e.s. 400 | e-glades | emgel | e-mycin | e-mycin e | eritrocina | eritromicina | eryacne 2 | eryacne 4 | eryc | eryc 125 | erycette | eryc sprinkles | eryderm | erygel | erymax | erymax sprinkle | erymin | erypar | eryped | ery-tab | erythomycin | erythra-derm | erythro 200 | erythrocin | erythrocin 500 | erythrocin acne pack | erythrocin ethyl succinate | erythrocin stearate | erythroden | erythromycin | erythromycin a | erythromycin a 11,12-carbonate | erythromycin a carbonate | erythromycin a cyclic 11,12-carbonate | erythromycin-ammonium bituminosulfonate | erythromycin, ammonium bituminosulfonate drug combination | erythromycin c | erythromycin cyclic carbonate | érythromycine | erythromycin estolate | erythromycin ethylsuccinate | erythromycin ethyl succinate | erythromycin gluceptate | erythromycin glucoheptonate | erythromycin-ichthammol | erythromycin lactobionate | erythromycin lauryl sulfate, propionyl | erythromycin propionate | erythromycin propionate lauryl sulfate | erythromycin stearate | erythromycinum | erythromycin - zinc acetate | erythromycin, zinc acetate drug combination | erythroped | erythroped a | erythroped fte | erythroped fte sf | erythroped pi | erythroped pi sf | erythroped sf | erythro-statin | erytromycin | e-solve 2 | ethril 250 | ethril 500 | gallimycin | ilosone | ilotycin | ilotycin gluceptate | isotrexin | kerymax | nyc 0462 | oftalmolosa cusi eritromicina | paediathrocin | pce | pediamycin | pediamycin 400 | pfizer-e | primacine | propiocine | propionyl eryhthromycin | propionyl erythromicin | propionylerythromycin | propionyl erythromycin lauryl sulfate | retcin | robimycin | rommix 125 | rommix 250 ec | rommix 500 ec | r-p mycin | sansac | staticin | stiemycin | superfact | tiloryth | t-stat | wyamycin | wyamycin e | wyamycin s | zineryt

Organizations (133)

Research & Development (80)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (56)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (62)

Approved Indications (10)


 

Acne Vulgaris

Diphtheria (approved 1965)

Endocarditis, Bacterial

Erythrasma (approved 1972)

Gastroparesis

Listeriosis (approved 1972)

Pneumonia

Pneumonia, Mycoplasma (approved 1965)

Skin Diseases, Infectious (approved 1972)

Staphylococcal Skin Infections

Experimental Indications - Clinical Trial Phases 1-4 (55)


 

Acne Vulgaris (Phase 4)

Albinism, Oculocutaneous (Phase 1/Phase 2)

Allergy and Immunology (Phase 4)

Asthma (Phase 4)

Blepharitis (Phase 4)

Breast Neoplasms (Phase 2)

Bronchiolitis (Phase 4)

Bronchiolitis Obliterans (Phase 4)

Bulimia Nervosa (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Chlamydia (Phase 2)

Chlamydia Infections (Phase 3)

Colorectal Neoplasms (Phase 2)

COVID-19 (Phase 4)

Diabetes Mellitus, Type 1 (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Epidermolysis Bullosa (Phase 3)

Erectile Dysfunction (Phase 1)

Eyelid Diseases (Phase 4)

Feeding and Eating Disorders (Phase 2)

Gastrectomy (Phase 2)

Gastric Emptying (Phase 2)

Gastrointestinal Hemorrhage (Phase 3)

Gastroparesis (Phase 2)

General Surgery (Phase 4)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 1)

Hematemesis (Phase 3)

Hepacivirus (Phase 1)

Hermanski-Pudlak Syndrome (Phase 1/Phase 2)

HIV Infections (Phase 3)

Infant, Premature (Phase 3)

Infertility (Phase 3)

Intestinal Neoplasms (Phase 3)

Intestinal Polyposis (Phase 4)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Metabolic Diseases (Phase 1/Phase 2)

Nausea (Phase 4)

Obesity (Phase 4)

Ophthalmia Neonatorum (Phase 3)

Pancreatitis (Phase 4)

Pharmacokinetics (Phase 1)

Platelet Storage Pool Deficiency (Phase 1/Phase 2)

Pneumonia (Phase 3)

Psoriasis (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 2/Phase 3)

Pulmonary Fibrosis (Phase 1/Phase 2)

Renal Insufficiency (Phase 1)

Respiratory Aspiration of Gastric Contents (Phase 2)

Skin Neoplasms (Phase 4)

Stomach Diseases (Early Phase 1)

Stomach Neoplasms (Phase 2)

Surgical Wound (Phase 4)

Surgical Wound Infection (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 73
  • # of Trial Organizations: 80

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue